- Posted in Resource Library

Beyond Dystrophin Panel

This conference session provides insight and updates from companies whose therapies target critical aspects of the Duchenne disease process that occur alongside reductions in dystrophin.

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

See more from same speaker

Mindy Cameron

Patient Advocacy Lead

Santhera Pharmaceuticals

See more from same speaker

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

See more from same speaker

Daniel Paulson, MD

Vice President of Clinical Development

Capricor Therapeutics

See more from same speaker

Han Phan, MD

Director

Rare Disease Research, LLC

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

Related Resources

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate